Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Does not exhibit phospholipase nor triacylglycerol lipase activity, able to hydrolyze only short chain substrates due to its shallow active site (By similarity).. Additionally we are shipping LYPLAL1 Proteins (6) and many more products for this protein.
Showing 10 out of 38 products:
Human Polyclonal LYPLAL1 Primary Antibody for ELISA, WB - ABIN334430
Steinberg, Kemp, Watt: Adipocyte triglyceride lipase expression in human obesity. in American journal of physiology. Endocrinology and metabolism 2007
Among Mexicans, the PNPLA3 (show PNPLA3 Antibodies) (rs738409), LYPLAL1 (rs12137855), PPP1R3B (show PPP1R3B Antibodies) (rs4240624), and GCKR (show GCKR Antibodies) (rs780094) polymorphisms may be associated with a greater risk of chronic liver disease among overweight adults.
Data provide evidence that variants of MC4R (show MC4R Antibodies) and LYPLAL1 modulate body fat distribution with sexual dimorphism in a Chinese population.
Our results suggest that LYPLAL1 rs4846567 and NISCH (show NISCH Antibodies) rs6784615 may influence fat distribution in the Japanese population.
genetic association studies in Danish population: Quantitative metabolic phenotypes in obesity are associated with SNP in various genes: LYPLAL1 (rs4846567) is associated with waist-hip ratio and insulin (show INS Antibodies) sensitivity in women.
Gene-treatment interactions were observed for short-term weight loss. (LYPLAL1 rs2605100, Plifestyle*SNP = 0.032)
LYPLAL1 exhibits neither phospholipase nor triacylglycerol lipase activity, but rather accepts short-chain substrates
central obesity-associated variants in LYPLAL1, NRXN3 (show NRXN3 Antibodies), MSRA (show MSRA Antibodies), and TFAP2B (show TFAP2B Antibodies)
TFAP2B (show TFAP2B Antibodies), LYPLAL1 and MSRA (show MSRA Antibodies) are associated with adiposity and fat distribution.
Lyplal1 mRNA was up-regulated during adipogenesis and enriched in mature adipocytes through a PPARgamma (show PPARG Antibodies)-independent mechanism. overexpression and knockdown of Lyplal1 did not perturb adipogenesis, triacylglycerol accumulation and/or insulin (show INS Antibodies) signaling.
Does not exhibit phospholipase nor triacylglycerol lipase activity, able to hydrolyze only short chain substrates due to its shallow active site (By similarity).
lysophospholipase-like protein 1
, lysophospholipase-like 1
, Lysophospholipase-like protein 1